Fifty Years of Surgery for Pancreatic Cancer.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Pancreatic Ductal
/ drug therapy
Chemotherapy, Adjuvant
/ methods
Humans
Laparoscopy
/ methods
Neoadjuvant Therapy
/ methods
Pancreatectomy
/ methods
Pancreatic Neoplasms
/ drug therapy
Pancreaticoduodenectomy
/ methods
Time Factors
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
3
8
2021
Statut:
ppublish
Résumé
The surgical treatment of pancreatic cancer (PDAC) has seen sweeping changes during the past 5 decades. Up to the middle of the 20th century resection rates were below 5%, but the numbers of curative resections for PDAC are now continuously increasing due to improved neoadjuvant treatment concepts as well as progress in surgical techniques and perioperative management. During the same period, mortality rates after pancreatic surgery have decreased considerably and are now less than 5%. One of the most important cornerstones of reduced mortality has been the concentration of PDAC surgery in specialized centers. In addition, the management of postoperative complications has improved greatly as a result of optimized interdisciplinary teamwork. Adjuvant chemotherapy has become the reference treatment in resected PDAC, achieving significantly prolonged survival. Moreover, the concept of borderline resectable PDAC has emerged to characterize tumors with increased risk for tumor-positive resection margins or worse outcome. The best treatment strategy for borderline resectable PDAC is currently under debate, whereas neoadjuvant therapy has become established as a beneficial treatment option for patients with locally advanced PDAC, enabling conversion surgery in up to 60% of cases. This review article summarizes the principal changes in PDAC surgery during the past 50 years.
Identifiants
pubmed: 32833940
doi: 10.1097/MPA.0000000000001634
pii: 00006676-202009000-00001
doi:
Types de publication
Journal Article
Portrait
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1005-1013Références
Mann O, Strate T, Schneider C, et al. Surgery for advanced and metastatic pancreatic cancer—current state and perspectives. Anticancer Res. 2006;26:681–686.
Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995;82:111–115.
Crile G Jr. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet. 1970;130:1049–1053.
Shapiro TM. Adenocarcinoma of the pancreas: a statistical analysis of biliary bypass vs Whipple resection in good risk patients. Ann Surg. 1975;182:715–721.
Michelassi F, Erroi F, Dawson PJ, et al. Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg. 1989;210:544–556.
Nakase A, Matsumoto Y, Uchida K, et al. Surgical treatment of cancer of the pancreas and the periampullary region: cumulative results in 57 institutions in Japan. Ann Surg. 1977;185:52–57.
Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg. 1997;226:248–257; discussion 257–260.
Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 1990;211:447–458.
Gouma DJ, van Geenen RC, van Gulik TM, et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000;232:786–795.
Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–594.
Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247:456–462.
Hartwig W, Werner J, Jäger D, et al. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14:e476–e485.
Büchler MW, Wagner M, Schmied BM, et al. Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg. 2003;138:1310–1315.
Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899–903.
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024.
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–2406.
Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173–180.
Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2019;68:130–139.
Michalski CW, Liu B, Heckler M, et al. Underutilization of surgery in Periampullary cancer treatment. J Gastrointest Surg. 2019;23:959–965.
Klaiber U, Schnaidt ES, Hinz U, et al. Prognostic factors of survival after neoadjuvant treatment and resection for initially unresectable pancreatic cancer. Ann Surg. 2019 Mar 20. [Epub ahead of print].
Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264:457–463.
Neoptolemos JP, Russell RC, Bramhall S, et al. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK pancreatic cancer group. Br J Surg. 1997;84:1370–1376.
Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–1137.
Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117–2127.
Lidsky ME, Sun Z, Nussbaum DP, et al. Going the extra mile: improved survival for pancreatic cancer patients traveling to high-volume centers. Ann Surg. 2017;266:333–338.
Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: the new R-status counts. Ann Surg. 2017;265:565–573.
Hank T, Hinz U, Tarantino I, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br J Surg. 2018;105:1171–1181.
Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269:520–529.
Hartwig W, Gluth A, Hinz U, et al. Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer. Br J Surg. 2016;103:1683–1694.
Del Chiaro M, Rangelova E, Halimi A, et al. Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. HPB (Oxford). 2019;21:219–225.
Hartwig W, Vollmer CM, Fingerhut A, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery. 2014;156:1–14.
Weitz J, Rahbari N, Koch M, et al. The “artery first” approach for resection of pancreatic head cancer. J Am Coll Surg. 2010;210:e1–e4.
Hackert T, Buchler MW. An innovative technique for pancreatic head resection: the “uncinate first” approach. Surg Technol Int. 2011;21:92–96.
Moore GE, Sako Y, Thomas LB. Radical pancreatoduodenectomy with resection and reanastomosis of the superior mesenteric vein. Surgery. 1951;30:550–553.
Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973;73:307–320.
Weitz J, Kienle P, Schmidt J, et al. Portal vein resection for advanced pancreatic head cancer. J Am Coll Surg. 2007;204:712–716.
Wang X, Demir IE, Schorn S, et al. Venous resection during pancreatectomy for pancreatic cancer: a systematic review. Transl Gastroenterol Hepatol. 2019;4:46.
Turrini O, Ewald J, Barbier L, et al. Should the portal vein be routinely resected during pancreaticoduodenectomy for adenocarcinoma? Ann Surg. 2013;257:726–730.
Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–988.
Hackert T, Schneider L, Büchler MW. Current state of vascular resections in pancreatic cancer surgery. Gastroenterol Res Pract. 2015;2015:120207.
Allema JH, Reinders ME, van Gulik TM, et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg. 1994;81:1642–1646.
Castleberry AW, White RR, De La Fuente SG, et al. The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Ann Surg Oncol. 2012;19:4068–4077.
Worni M, Castleberry AW, Clary BM, et al. Concomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10,206 patients. JAMA Surg. 2013;148:331–338.
Giovinazzo F, Turri G, Katz MH, et al. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. Br J Surg. 2016;103:179–191.
Ravikumar R, Sabin C, Abu Hilal M, et al. Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study. J Am Coll Surg. 2014;218:401–411.
Xie ZB, Li J, Gu JC, et al. Pancreatoduodenectomy with portal vein resection favors the survival time of patients with pancreatic ductal adenocarcinoma: a propensity score matching analysis. Oncol Lett. 2019;18:4563–4572.
Klaiber U, Mihaljevic A, Hackert T. Radical pancreatic cancer surgery—with arterial resection. Transl Gastroenterol Hepatol. 2019;4:8.
Mollberg N, Rahbari NN, Koch M, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254:882–893.
Hackert T, Weitz J, Buchler MW. Splenic artery use for arterial reconstruction in pancreatic surgery. Langenbecks Arch Surg. 2014;399:667–671.
Sanjay P, Takaori K, Govil S, et al. ‘Artery-first’ approaches to pancreatoduodenectomy. Br J Surg. 2012;99:1027–1035.
Klompmaker S, de Rooij T, Korteweg JJ, et al. Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer. Br J Surg. 2016;103:941–949.
Klompmaker S, Peters NA, van Hilst J, et al. Outcomes and risk score for distal pancreatectomy with celiac axis resection (DP-CAR): an international multicenter analysis. Ann Surg Oncol. 2019;26:772–781.
Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–1046.
Vauthey JN, Dixon E. AHPBA/SSO/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference. Ann Surg Oncol. 2009;16:1725–1726.
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1028–1061.
Hackert T, Ulrich A, Buchler MW. Borderline resectable pancreatic cancer. Cancer Lett. 2016;375:231–237.
Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.
Salky BA, Edye M. Laparoscopic pancreatectomy. Surg Clin North Am. 1996;76:539–545.
Melvin WS, Needleman BJ, Krause KR, et al. Robotic resection of pancreatic neuroendocrine tumor. J Laparoendosc Adv Surg Tech A. 2003;13:33–36.
de Rooij T, van Hilst J, van Santvoort H, et al. Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial. Ann Surg. 2019;269:2–9.
van Hilst J, de Rooij T, Klompmaker S, et al. Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a pan-European propensity score matched study. Ann Surg. 2019;269:10–17.
Gavriilidis P, Roberts KJ, Sutcliffe RP. Comparison of robotic vs laparoscopic vs open distal pancreatectomy. A systematic review and network meta-analysis. HPB (Oxford). 2019;21:1268–1276.
Nickel F, Haney CM, Kowalewski KF, et al. Laparoscopic versus open pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled trials. Ann Surg. 2020;271:54–66.
van Hilst J, de Rooij T, Bosscha K, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol. 2019;4:199–207.
Kamarajah SK, Bundred J, Marc OS, et al. Robotic versus conventional laparoscopic pancreaticoduodenectomy a systematic review and meta-analysis. Eur J Surg Oncol. 2020;46:6–14.
Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576–1585.
Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308:147–156.
Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504–512.
Rangelova E, Wefer A, Persson S, et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann Surg. 2019 Apr 2. [Epub ahead of print].
Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270:340–347.
Hackert T, Strobel O, Michalski CW, et al. The TRIANGLE operation—radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB (Oxford). 2017;19:1001–1007.
Schneider M, Strobel O, Hackert T, et al. Pancreatic resection for cancer—the Heidelberg technique. Langenbecks Arch Surg. 2019;404:1017–1022.
Johna S. Allen Oldfather Whipple: a distinguished surgeon and historian. Dig Surg. 2003;20:154–162.
Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg. 1935;102:763–779.
Whipple AO. Pancreaticoduodenectomy for islet carcinoma: a five-year follow-up. Ann Surg. 1945;121:847–852.
Traverso LW, Longmire WP Jr. Preservation of the pylorus in pancreaticoduodenectomy a follow-up evaluation. Ann Surg. 1980;192:306–310.
Traverso LW. The pylorus preserving Whipple procedure for the treatment of chronic pancreatitis. Swiss Surg. 2000;6:259–263.
Fernández-del Castillo C, Sarr MG. Andrew L. Warshaw, MD: modern pioneer of pancreatic surgery. Surgery. 2012;152(3 Suppl 1):S1–S3.
Warshaw AL, Tepper JE, Shipley WU. Laparoscopy in the staging and planning of therapy for pancreatic cancer. Am J Surg. 1986;151:76–80.
Warshaw AL. Conservation of the spleen with distal pancreatectomy. Arch Surg. 1988;123:550–553.
Javed AA, Weiss MJ, Wolfgang CL. John L. Cameron, MD: overview of his career. Ann Surg. 2018;267(2S Suppl 2):S2.
Javed AA, Weiss MJ. John L. Cameron: a historical perspective. Ann Surg. 2018;267(2S Suppl 2):S40–S44.
Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg. 1987;206:358–365.
Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015;220:530–536.
Hines OJ. Howard A. Reber, M.D., Distinguished Professor of Surgery, UCLA School of Medicine. Langenbecks Arch Surg. 2010;395:593–594.
Todd KE, Gloor B, Lane JS, et al. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole. J Gastrointest Surg. 1998;2:159–166.
Kadera BE, Sunjaya DB, Isacoff WH, et al. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. JAMA Surg. 2014;149:145–153.
Beger HG, Krautzberger W, Bittner R, et al. Duodenum-sparing pancreas head resection in chronic pancreatitis—results after 10 years' use. Langenbecks Arch Chir. 1984;362:229–236.
Gloor B, Friess H, Uhl W, et al. A modified technique of the Beger and Frey procedure in patients with chronic pancreatitis. Dig Surg. 2001;18:21–25.
Japanese Society of Hepato-Biliary-Pancreatic Surgery. October 4, 2019. Available at: http://www.jshbps.jp/modules/en/index.php?content_id=27#founders. Accessed May 24, 2020.
Hanyu F, Takasaki K. Pancreatoduodenectomy. Tokyo, Japan: Springer; 1997.
Hatori T, Imaizumi T, Harada N, et al. Appraisal of the Imaizumi modification of the Beger procedure: the TWMU experience. J Hepatobiliary Pancreat Sci. 2010;17:752–757.
Endo I, Yamamoto M. Professor Tadahiro Takada: 25 years of distinguished service as editor-in-chief of JHBPS. J Hepatobiliary Pancreat Sci. 2019;26:89–92.
Takada T. Curriculum Vitae. Available at: http://www.med.teikyo-u.ac.jp/~takada/iryou/CV.html. Accessed May 24, 2020.